The kidney in congestive heart failure: 'Are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'

European Journal of Heart Failure

Volumn 16, Issue 2, 2014, Pages 133-142

  Verbrugge, Frederik H ^a,b   Dupont, Matthias ^a   Steels, Paul ^b   Grieten, Lars ^a,b   Swennen, Quirine ^b   Tang, W H Wilson ^c   Mullens, Wilfried ^a,b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Congestive heart failure; Diuretics; Kidney; Natriuretic peptides; Sodium

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYCLIC GMP; CYSTATIN C; DIURETIC AGENT; LOOP DIURETIC AGENT; NESIRITIDE; PHOSPHODIESTERASE V; SODIUM; VASODILATOR AGENT;

AUTOREGULATION; CAPILLARY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DISEASE COURSE; DIURETIC THERAPY; EXTRACELLULAR SPACE; FREE WATER CLEARANCE; GLOMERULAR FILTRATION BARRIER; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; HYDROSTATIC PRESSURE; HYPONATREMIA; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; KIDNEY DISTAL TUBULE; KIDNEY DYSFUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE PRESSURE; KIDNEY VASCULAR RESISTANCE; LYMPH FLOW; MACULA DENSA; MEAN ARTERIAL PRESSURE; NATRIURESIS; NEPHRON; ONCOTIC PRESSURE; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; SODIUM ABSORPTION; SODIUM BALANCE; SODIUM BLOOD LEVEL; SODIUM LOAD; ULTRAFILTRATION; VAGUS NERVE STIMULATION;

CONGESTIVE HEART FAILURE; DIURETICS; KIDNEY; NATRIURETIC PEPTIDES; SODIUM;

ATRIAL NATRIURETIC FACTOR; DIURETICS; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULES; NATRIURETIC PEPTIDE, BRAIN; RENAL CIRCULATION; RENAL INSUFFICIENCY, CHRONIC; SODIUM; WATER-ELECTROLYTE IMBALANCE;

EID: 84896988257     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.35     Document Type: Review

References (86)

1. Skorecki KL, Brenner BM. Body fluid homeostasis in man. A contemporary overview. Am J Med 1981;70:77-88.
2. Adams KF Jr, Fonarow GC, Emerman CL, Le Jemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216.
3. Hillege HL, Girbes AR, De Kam PJ, Boomsma F, De Zeeuw D, Charlesworth A, Hampton JR, Van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-210.
4. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-67.
5. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265-272.
6. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011;4:685-691.
7. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei Cas L. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 2012;5:54-62.
8. Braam B, Cupples WA, Joles JA, Gaillard C. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev 2012;17:161-175.
9. Carmines PK, Inscho EW, Gensure RC. Arterial pressure effects on preglomerular microvasculature of juxtamedullary nephrons. Am J Physiol 1990;258:F94-F102.
10. Just A, Arendshorst WJ. Dynamics and contribution of mechanisms mediating renal blood flow autoregulation. Am J Physiol Regul Integr Comp Physiol 2003;285:R619-R631.
11. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998;274:R263-R279.
12. Thomson SC, Blantz RC. Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis. J Am Soc Nephrol 2008;19:2272-2275.
13. Smilde TD, Damman K, Van Der Harst P, Navis G, Westenbrink BD, Voors AA, Boomsma F, Van Veldhuisen DJ, Hillege HL. Differential associations between renal function and 'modifiable' risk factors in patients with chronic heart failure. Clin Res Cardiol 2009;98:121-129.
14. Testani JM, Coca SG, McCauley BD, Shannon RP, Kimmel SE. Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes. Eur J Heart Fail 2011;13:877-884.
15. Dupont M, Mullens W, Finucan M, Taylor DO, Starling RC, Tang WH. Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. Eur J Heart Fail 2013;15:433-440.
16. Di Bona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75-197.
17. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008;51:1268-1274.
18. Damman K, Van Deursen VM, Navis G, Voors AA, Van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009;53:582-588.
19. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-596.
20. Maxwell MH, Breed ES, Schwartz IL. Renal venous pressure in chronic congestive heart failure. J Clin Invest 1950;29:342-348.
21. Winton FR. The influence of venous pressure on the isolated mammalian kidney. J Physiol 1931;72:49-61.
22. Blake WD, Wegria R, Keating RP, Ward HP. Effect of increased renal venous pressure on renal function. Am J Physiol 1949;157:1-13.
23. Doty JM, Saggi BH, Sugerman HJ, Blocher CR, Pin R, Fakhry I, Gehr TW, Sica DA. Effect of increased renal venous pressure on renal function. J Trauma 1999;47:1000-1003.
24. Wesson LG. Physiology of the Human Kidney. New York: Grune & Stratton; 1969. p126-128.
25. Kastner PR, Hall JE, Guyton AC. Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. Am J Physiol 1982;243:F260-F264.
26. Gibson DG, Marshall JC, Lockey E. Assessment of proximal tubular sodium reabsorption during water diuresis in patients with heart disease. Br Heart J 1970;32:399-405.
27. Lewy JE, Windhager EE. Peritubular control of proximal tubular fluid reabsorption in the rat kidney. Am J Physiol 1968;214:943-954.
28. Grandchamp A, Boulpaep EL. Pressure control of sodium reabsorption and intercellular backflux across proximal kidney tubule. J Clin Invest 1974;54:69-82.
29. Gottschalk CW, Mylle M. Micropuncture study of pressures in proximal tubules and peritubular capillaries of the rat kidney and their relation to ureteral and renal venous pressures. Am J Physiol 1956;185:430-439.
30. Burnett JC Jr, Knox FG. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol 1980;238:F279-F282.
31. Haddy FJ, Scott J, Fleishman M, Emanuel D. Effect of change in renal venous pressure upon renal vascular resistance, urine and lymph flow rates. Am J Physiol 1958;195:97-110.
32. Lebrie SJ, Mayerson HS. Influence of elevated venous pressure on flow and composition of renal lymph. Am J Physiol 1960;198:1037-1040.
33. Ott CE, Haas JA, Cuche JL, Knox FG. Effect of increased peritubule protein concentration on proximal tubule reabsorption in the presence and absence of extracellular volume expansion. J Clin Invest 1975;55:612-620.
34. Lote CJ, Snape BM. Collecting duct flow rate as a determinant of equilibration between urine and renal papilla in the rat in the presence of a maximal antidiuretic hormone concentration. J Physiol 1977;270:533-544.
35. Allen GG, Barratt LJ. Effect of aldosterone on the transepithelial potential difference of the rat distal tubule. Kidney Int 1981;19:678-686.
36. Woodhall PB, Tisher CC. Response of the distal tubule and cortical collecting duct to vasopressin in the rat. J Clin Invest 1973;52:3095-3108.
37. Schrier RW. Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol 2010;6:61.
38. Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, Fowler MB. Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:70-78.
39. Kim GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 2004;24:595-605.
40. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989;36:682-689.
41. Beltowski J. Guanylin and related peptides. J Physiol Pharmacol 2001;52:351-375.
42. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol 2008;101:3-8.
43. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328.
44. Fontoura BM, Nussenzveig DR, Pelton KM, Maack T. Atrial natriuretic factor receptors in cultured renomedullary interstitial cells. Am J Physiol 1990;258:C692-C699.
45. Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Hernandez AF. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF. J Am Coll Cardiol 2013;62:1177-1183.
46. McKie PM, Schirger JA, Costello-Boerrigter LC, Benike SL, Harstad LK, Bailey KR, Hodge DO, Redfield MM, Simari RD, Burnett JC Jr, Chen HH. Impaired natriuretic and renal endocrine response to acute volume expansion in preclinical systolic and diastolic dysfunction. J Am Coll Cardiol 2011;58:2095-2103.
47. Mullens W, Tang WH. The early intertwining of the heart and the kidney through an impaired natriuretic response to acute volume expansion. J Am Coll Cardiol 2011;58:2104-2105.
48. Bryan PM, Xu X, Dickey DM, Chen Y, Potter LR. Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. Am J Physiol Renal Physiol 2007;292:F1636-F1644.
49. Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 1999;100:2443-2448.
50. Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC Jr. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol 2006;17:2742-2747.
51. Bishara B, Abu-Saleh N, Awad H, Ghrayeb N, Goltsman I, Aronson D, Khamaysi I, Assady S, Armaly Z, Haddad S, Haddad E, Abassi Z. Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure. Eur J Heart Fail 2012;14:1104-1111.
52. Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, Paganini E, Tang WH. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008;51:300-306.
53. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008;52:347-356.
54. Madan VD, Novak E, Rich MW. Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia. Circ Heart Fail 2011;4:637-743.
55. Lee SE, Choi DJ, Yoon CH, Oh IY, Jeon ES, Kim JJ, Cho MC, Chae SC, Ryu KH, Oh BH. Improvement of hyponatraemia during hospitalisation for acute heart failure is not associated with improvement of prognosis: an analysis from the Korean Heart Failure (KorHF) registry. Heart 2012;98:1798-1804.
56. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331.
57. Bell NH, Schedl HP, Bartter FC. An explanation for abnormal water retention and hypoosmolality in congestive heart failure. Am J Med 1964;36:351-360.
58. Schedl HP, Bartter FC. An explanation for and experimental correction of the abnormal water diuresis in cirrhosis. J Clin Invest 1960;39:248-261.
59. Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am 2005;89:457-473.
60. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
61. Dupont M, Wu Y, Hazen SL, Tang WH. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail 2012;5:602-609.
62. Taub PR, Borden KC, Fard A, Maisel A. Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome. Expert Rev Cardiovasc Ther 2012;10:657-667.
63. Dupont M, Shrestha K, Singh D, Awad A, Kovach C, Scarcipino M, Maroo AP, Tang WH. Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. Eur J Heart Fail 2012;14:597-604.
64. Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, Van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G, Tavazzi L, Latini R. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011;32:2705-2712.
65. Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999;106:90-96.
66. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, Smith FE, Lane KA, Adams LD, Tierney WM, Brater DC. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001;111:513-520.
67. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002;4:507-513.
68. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. Eur J Heart Fail 2003;5:793-801.
69. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, Le Winter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.
70. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
71. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311-1315.
72. Gotsman I, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail 2012;18:694-701.
73. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
74. Zannad F, McMurray JJ, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
75. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 1997;29:367-372.
76. Seely JF, Dirks JH. Micropuncture study of hypertonic mannitol diuresis in the proximal and distal tubule of the dog kidney. J Clin Invest 1969;48:2330-2340.
77. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
78. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206.
79. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-393.
80. Stramba-Badiale M, Vanoli E, De Ferrari GM, Cerati D, Foreman RD, Schwartz PJ. Sympathetic-parasympathetic interaction and accentuated antagonism in conscious dogs. Am J Physiol 1991;260:H335-H340.
81. Nozawa T, Igawa A, Fujii N, Kato B, Yoshida N, Asanoi H, Inoue H. Effects of longterm renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels 2002;16:51-56.
82. Hauptman PJ, Mann DL. The vagus nerve and autonomic imbalance in heart failure: past, present, and future. Heart Fail Rev 2011;16:97-99.
83. Ali SS, Olinger CC, Sobotka PA, Dahle TG, Bunte MC, Blake D, Boyle AJ. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail 2009;15:1-4.
84. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, Le Winter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296-2304.
85. Koch M, Haastert B, Kohnle M, Rump LC, Kelm M, Trapp R, Aker S. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail 2012;14:530-539.
86. Nunez J, Gonzalez M, Minana G, Garcia-Ramon R, Sanchis J, Bodi V, Nunez E, Puchades MJ, Palau P, Merlos P, Llacer A, Miguel A. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 2012;14:540-548.